Literature DB >> 9362380

Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro.

S Iacovacci1, A Manzin, S Barca, M Sargiacomo, A Serafino, M B Valli, G Macioce, H J Hassan, A Ponzetto, M Clementi, C Peschle, G Carloni.   

Abstract

The molecular features of hepatitis C virus (HCV) replication in human fetal hepatocytes (HFHs) were addressed in this study. Using a competitive reverse-transcription polymerase chain reaction (RT-PCR) assay for the quantitation of HCV-RNA molecules, the highest level of viral replication was detected 30 days' postinfection. At this time point, viral particles of 41 to 45 nm in diameter accumulated in the cell cytoplasm. Their density in cell extracts and culture medium was distributed between heavy (1.180-1.360 g/cm3) and light fractions (1.105-1.050 g/cm3) of a sucrose gradient, while, in the serum inoculum, they had a positive fraction at 1.180 g/cm3. In infected HFHs, minus-strand HCV RNA was observed in fractions displaying a sedimentation coefficient of 28 S to 18 S, while plus-strand HCV RNA showed a peak restricted to the 21 S fraction; the HCV RNA of serum inoculum had a sedimentation coefficient of 38 to 40 S, which revealed the presence of HCV RNA of unique positive polarity. The 21 S RNA fraction of cell extracts was resistant to 20 minutes of RNase I digestion, while the same incubation time totally inactivated a comparable amount of HCV RNA purified from the serum inoculum, revealing the presence of completely and/or partially double-stranded HCV-RNA molecules in the infected cells. Detection in HFHs of replicative forms and replicative intermediates suggests that the dynamic profile of HCV replication in these cells is similar to that described in other flaviviruses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9362380     DOI: 10.1002/hep.510260535

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes.

Authors:  Catherine A Lázaro; Ming Chang; Weiliang Tang; Jean Campbell; Daniel G Sullivan; David R Gretch; Lawrence Corey; Robert W Coombs; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 2.  Cell culture systems for the hepatitis C virus.

Authors:  Gilles Duverlie; Czeslaw Wychowski
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

3.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

4.  HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro.

Authors:  Mostafa K el-Awady; Ashraf A Tabll; Yasmine S el-Abd; Mahmoud M Bahgat; Hussein A Shoeb; Samar S Youssef; Noha G Bader el-Din; el-Rashdy M Redwan; Maha el-Demellawy; Moataza H Omran; Wael T el-Garf; Said A Goueli
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

5.  New Methods in Tissue Engineering: Improved Models for Viral Infection.

Authors:  Vyas Ramanan; Margaret A Scull; Timothy P Sheahan; Charles M Rice; Sangeeta N Bhatia
Journal:  Annu Rev Virol       Date:  2014-11       Impact factor: 10.431

6.  An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice.

Authors:  Martha J Harding; Christin M Lepus; Thomas F Gibson; Benjamin R Shepherd; Scott A Gerber; Morven Graham; Frank X Paturzo; Christoph Rahner; Joseph A Madri; Alfred L M Bothwell; Brett D Lindenbach; Jordan S Pober
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  Subgenomic HCV RNA replication and its localization in the nucleus of the infected cells.

Authors:  Zaki Monawar Eisa
Journal:  Saudi J Biol Sci       Date:  2011-02-03       Impact factor: 4.219

8.  Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Authors:  Robert B Perni; Susan J Almquist; Randal A Byrn; Gurudatt Chandorkar; Pravin R Chaturvedi; Lawrence F Courtney; Caroline J Decker; Kirk Dinehart; Cynthia A Gates; Scott L Harbeson; Angela Heiser; Gururaj Kalkeri; Elaine Kolaczkowski; Kai Lin; Yu-Ping Luong; B Govinda Rao; William P Taylor; John A Thomson; Roger D Tung; Yunyi Wei; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

Authors:  Emmanuel G Cormier; Robert J Durso; Fotini Tsamis; Lise Boussemart; Catherine Manix; William C Olson; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-15       Impact factor: 11.205

10.  CD81 is an entry coreceptor for hepatitis C virus.

Authors:  Emmanuel G Cormier; Fay Tsamis; Francis Kajumo; Robert J Durso; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.